FindTrial
Sign In

Fractional CO2 laser therapy in postmenopausal genitourinary syndrome

To evaluate the effectiveness of fractional CO2 laser in postmenopausal genitourinary syndrome - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/07/091363
Enrollment
32
Registered
2025-07-22
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N998- Other intraoperative and postprocedural complications and disorders of genitourinary system

Interventions

Intervention1: Nil: Nil Control Intervention1: Nil: Nil

Sponsors

Room No
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Postmenopausal individuals aged 45-70 years. Clinically diagnosed with genitourinary syndrome of menopause. Presence of symptoms such as vaginal dryness, itching, dyspareunia, and urinary discomfort. Absence of contraindications for fractional CO2 laser therapy. Patients giving written informed consent will be taken Early UV prolapse (stages more than 2)

Exclusion criteria

Exclusion criteria: History of pelvic malignancy. Active genital or urinary infections. Previous pelvic radiation therapy. Severe coagulation disorders or use of anticoagulant medication History of autoimmune diseases affecting the genitourinary system Previous bone surgery or having implant Patient having organ prolapse greater than stage 2 Patients who received hormonal replacement therapy within 6 month Patients who received vaginal medication/treatment within 1 month Inability to comply with the study protocol or attend scheduled follow-up visits

Design outcomes

Primary

MeasureTime frame
Improvement in genitourinary symptoms such as vaginal dryness, burning, irritation, and dyspareunia, assessed using validated scoring systems like the Vaginal Health Index Score (VHIS) or Visual Analog Scale (VAS), post-treatment.Timepoint: Improvement in genitourinary symptoms such as vaginal dryness, burning, irritation, and dyspareunia, assessed using validated scoring systems like the Vaginal Health Index Score (VHIS) or Visual Analog Scale (VAS), post-treatment.—

Secondary

MeasureTime frame
patient satisfaction scores, quality of life improvement, and adverse effects complicationsTimepoint: patient satisfaction scores, quality of life improvement, and adverse effects complications—

Countries

India

Contacts

Public ContactSujata Deo

King Georges Medical University Lucknow

drsujata.2008@rediffmail.com9415152570

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026